CLINICAL STUDY
Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with noninsulin dependent diabetes mellitus
A serial intravascular ultrasound study
Tsutomu Takagi, MDa,
Takashi Akasaka, MDa,
Atsushi Yamamuro, MDa,
Yasuhiro Honda, MDa,
Takeshi Hozumi, MDa,
Shigefumi Morioka, MDa and
Kiyoshi Yoshida, MD, FACCb
a Division of Cardiology, Kobe General Hospital, Minatojima Nakamachi 4-6, Chuo-Ku, Kobe, Japan
b Division of Cardiology, Department of Internal Medicine, Kawasaki Medical University, Kurashiki, Japan
Manuscript received October 25, 1999;
revised manuscript received April 24, 2000,
accepted June 21, 2000.
Reprint requests and correspondence: Dr. Tsutomu Takagi, Division of Cardiology, Kobe General Hospital, Minatojima Nakamachi 4-6, Chuo-Ku, Kobe, Japan tx-tkg{at}ka2.so-net.ne.jp
OBJECTIVES
The aim of the present study was to determine whether troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with noninsulin dependent diabetes mellitus (NIDDM).
BACKGROUND
Increased in-stent restenosis in patients with diabetes mellitus is due to accelerated neointimal tissue proliferation after coronary stent implantation. Troglitazone inhibits intimal hyperplasia in experimental animal models.
METHODS
We studied 62 stented lesions in 52 patients with plasma glucose levels (PG) 11.1 mmol/liter at 2 h after 75 g oral glucose load. The study patients were randomized into two groups: the troglitazone group of 25 patients with 29 stents, who were treated with 400 mg of troglitazone, and the control group of 27 patients with 33 stents. All patients underwent oral glucose tolerance tests before and after their six-month treatment period. The sum of PG ( PG) and the sum of insulin levels ( IRI) were measured. Serial (postintervention and at six-month follow-up) intravascular ultrasound studies were performed. Cross-sectional images within stents were taken at every 1 mm, using an automatic pullback. Stent areas (SA), lumen areas (LA), and intimal areas (IA = SA LA) were measured and averaged over a number of selected image slices. The intimal index was calculated as intimal index = averaged IA/averaged SA x 100%.
RESULTS
There were no differences between the two groups before treatment in PG (31.35 ± 3.07 mmol/liter vs. 32.89 ± 4.87 mmol/liter, respectively, p = 0.2998) and IRI (219.6 ± 106.2 mU/liter vs. 209.2 ± 91.6 mU/liter, respectively, p = 0.8934). However, reductions in PG at the six-month follow-up in the troglitazone group were significantly greater than those in the control group (21.4 ± 8.8% vs. 4.5 ± 7.4%, respectively, p < 0.0001). Likewise, decreases in IRI were greater in the troglitazone-treated group (31.4 ± 17.9% vs. 1.9 ± 15.1%, respectively, p < 0.0001). Although, there were no differences between the two groups in SA at postintervention (7.4 ± 2.2 mm2 vs. 7.3 ± 1.7 mm2, respectively, p = 0.9482) and at follow-up (7.3 ± 2.3 mm2 vs. 7.3 ± 1.8 mm2, respectively, p = 0.2307), the LA at follow-up in the troglitazone group was significantly greater than that in the control group (5.3 ± 1.7 mm2 vs. 3.7 ± 1.7 mm2, respectively, p = 0.0002). The IA at follow-up in the troglitazone group was significantly smaller than that in the control group (2.0 ± 0.9 mm2 vs. 3.5 ± 1.8 mm2, respectively, p < 0.0001). This was also true for intimal index (27.1 ± 11.5% vs. 49.0 ± 14.4%, respectively, p < 0.0001).
CONCLUSIONS
Serial intravascular ultrasound assessment shows that administration of troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with NIDDM.
|
Abbreviations and Acronyms
| | DM | = diabetes mellitus | | HDL | = high-density lipoprotein | | IA | = intimal areas | | IGT | = impaired glucose tolerance | | IRI | = immunoreactive insulin level | | IVUS | = intravascular ultrasound | | LA | = cross-sectional lumen areas | | LDL | = low-density lipoprotein | | MLD | = minimal lumen diameter | | NIDDM | = non-insulin dependent diabetes mellitus | | OGTT | = oral glucose tolerance test | | PDGF | = platelet-derived growth factor | | PG | = plasma glucose level | | SA | = cross-sectional stent areas | | VSMC | = vascular smooth muscle cell |
|
This article has been cited by other articles:

|
 |

|
 |
 
J. M. Kleinhenz, D. J. Kleinhenz, S. You, J. D. Ritzenthaler, J. M. Hansen, D. R. Archer, R. L. Sutliff, and C. M. Hart
Disruption of endothelial peroxisome proliferator-activated receptor-{gamma} reduces vascular nitric oxide production
Am J Physiol Heart Circ Physiol,
November 1, 2009;
297(5):
H1647 - H1654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H Kaneda, T Shiono, Y Miyashita, S Takahashi, Y Taketani, H Domae, J Matsumi, S Mizuno, Y Minami, K Sugitatsu, et al.
Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation
Heart,
July 1, 2009;
95(13):
1079 - 1084.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Takagi, H. Okura, Y. Kobayashi, T. Kataoka, H. Taguchi, I. Toda, K. Tamita, A. Yamamuro, Y. Sakanoue, A. Ito, et al.
A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
524 - 531.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ingbir, I. F. Schwartz, A. Shtabsky, I. Filip, R. Reshef, T. Chernichovski, N. Levin-Iaina, U. Rozovski, Y. Levo, and D. Schwartz
Rosiglitazone improves aortic arginine transport, through inhibition of PKC{alpha}, in uremic rats
Am J Physiol Renal Physiol,
August 1, 2008;
295(2):
F471 - F477.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. K. McGuire and S. E. Inzucchi
New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
Circulation,
January 22, 2008;
117(3):
440 - 449.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-C. Fang, Yeun Tarl Fresner Ng Jao, Yi-Chen, C.-L. Yu, C.-L. Chen, and S.-P. Wang
Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience
Angiology,
November 1, 2007;
58(5):
523 - 534.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Raggi and A. Bellasi
Review: Imaging to assess effect of medical therapy in patients with diabetes mellitus
The British Journal of Diabetes & Vascular Disease,
July 1, 2007;
7(4):
157 - 164.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Riche, R. Valderrama, and N. N. Henyan
Thiazolidinediones and Risk of Repeat Target Vessel Revascularization Following Percutaneous Coronary Intervention: A meta-analysis
Diabetes Care,
February 1, 2007;
30(2):
384 - 388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire
Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism
Diabetes and Vascular Disease Research,
September 1, 2006;
3(2):
65 - 71.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A K Mitra and D K Agrawal
In stent restenosis: bane of the stent era.
J. Clin. Pathol.,
March 1, 2006;
59(3):
232 - 239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nishio, M. Sakurai, T. Kusuyama, M. Shigemitsu, T. Fukui, K. Kawamura, S. Itoh, N. Konno, and T. Katagiri
A Randomized Comparison of Pioglitazone to Inhibit Restenosis After Coronary Stenting in Patients With Type 2 Diabetes
Diabetes Care,
January 1, 2006;
29(1):
101 - 106.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Soumian, R Gibbs, A Davies, and C Albrecht
mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease
J. Clin. Pathol.,
December 1, 2005;
58(12):
1255 - 1260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Marx, J. Wohrle, T. Nusser, D. Walcher, A. Rinker, V. Hombach, W. Koenig, and M. Hoher
Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Nondiabetic Patients
Circulation,
November 1, 2005;
112(18):
2792 - 2798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart
Peroxisome Proliferator-Activated Receptor {gamma} Ligands Stimulate Endothelial Nitric Oxide Production Through Distinct Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Mechanisms
Arterioscler Thromb Vasc Biol,
September 1, 2005;
25(9):
1810 - 1816.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Inzucchi, F. A. Masoudi, Y. Wang, M. Kosiborod, J. M. Foody, J. F. Setaro, E. P. Havranek, and H. M. Krumholz
Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project
Diabetes Care,
July 1, 2005;
28(7):
1680 - 1689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Choi, S.-K. Kim, S.-H. Choi, Y.-G. Ko, C.-W. Ahn, Y. Jang, S.-K. Lim, H.-C. Lee, and B.-S. Cha
Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes
Diabetes Care,
November 1, 2004;
27(11):
2654 - 2660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Chiquette, G. Ramirez, and R. DeFronzo
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Arch Intern Med,
October 25, 2004;
164(19):
2097 - 2104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Walcher and N. Marx
Insulin resistance and cardiovascular disease: the role of PPAR{gamma} activators beyond their anti-diabetic action
Diabetes and Vascular Disease Research,
October 1, 2004;
1(2):
76 - 81.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Circ. Res.,
May 14, 2004;
94(9):
1168 - 1178.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Chaves, A. G.M.R. Sousa, L. A. Mattos, A. Abizaid, R. Staico, F. Feres, M. Centemero, L. F. Tanajura, A. Abizaid, I. Pinto, et al.
Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated With or Without Abciximab: Results of the Diabetes Abciximab steNT Evaluation (DANTE) Randomized Trial
Circulation,
February 24, 2004;
109(7):
861 - 866.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. E.J. West, P. N. Ruygrok, C. M.C. Disco, M. W.I. Webster, W. K. Lindeboom, W. W. O'Neill, N. F. Mercado, and P. W. Serruys
Clinical and Angiographic Predictors of Restenosis After Stent Deployment in Diabetic Patients
Circulation,
February 24, 2004;
109(7):
867 - 873.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Corti, J. I. Osende, J. T. Fallon, V. Fuster, G. Mizsei, H. Jneid, S. D. Wright, W. F. Chaplin, and J. J. Badimon
The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging
J. Am. Coll. Cardiol.,
February 4, 2004;
43(3):
464 - 473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Takamori, H. Azuma, M. Kato, S. Hashizume, K.-i. Aihara, M. Akaike, K. Tamura, and T. Matsumoto
High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary Intervention
Circulation,
February 3, 2004;
109(4):
481 - 486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Roffi and E. J. Topol
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes
Eur. Heart J.,
February 1, 2004;
25(3):
190 - 198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. A. Hsueh and D. Bruemmer
Peroxisome Proliferator-Activated Receptor {gamma}: Implications for Cardiovascular Disease
Hypertension,
February 1, 2004;
43(2):
297 - 305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kornowski and S. Fuchs
Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions
J. Am. Coll. Cardiol.,
January 7, 2004;
43(1):
15 - 17.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. V. Desouza, S. N. Murthy, J. Diez, B. Dunne, A. S. Matta, V. A. Fonseca, and D. B. McNamara
Differential Effects of Peroxisome Proliferator Activator Receptor-{alpha} and {gamma} Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats
Journal of Cardiovascular Pharmacology and Therapeutics,
December 1, 2003;
8(4):
297 - 305.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Stephenson, J. Tunstead, A. Tsai, R. Gordon, S. Henderson, and H. M. Dansky
Neointimal Formation After Endovascular Arterial Injury Is Markedly Attenuated in db/db Mice
Arterioscler Thromb Vasc Biol,
November 1, 2003;
23(11):
2027 - 2033.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Phillips, K. G. Barringhaus, J. M. Sanders, Z. Yang, M. Chen, S. Hesselbacher, A. C. Czarnik, K. Ley, J. Nadler, and I. J. Sarembock
Rosiglitazone Reduces the Accelerated Neointima Formation After Arterial Injury in a Mouse Injury Model of Type 2 Diabetes
Circulation,
October 21, 2003;
108(16):
1994 - 1999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Smith
The CARDia trial protocol
Heart,
October 1, 2003;
89(10):
1125 - 1126.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Satoh, Y. Ogawa, T. Usui, T. Tagami, S. Kono, H. Uesugi, H. Sugiyama, A. Sugawara, K. Yamada, A. Shimatsu, et al.
Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect
Diabetes Care,
September 1, 2003;
26(9):
2493 - 2499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-H. Mak and D. P. Faxon
Clinical studies on coronary revascularization in patients with type 2 diabetes
Eur. Heart J.,
June 2, 2003;
24(12):
1087 - 1103.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Bruemmer, F. Yin, J. Liu, J. P. Berger, T. Kiyono, J. Chen, E. Fleck, A. J. Van Herle, B. M. Forman, and R. E. Law
Peroxisome Proliferator-Activated Receptor {gamma} Inhibits Expression of Minichromosome Maintenance Proteins in Vascular Smooth Muscle Cells
Mol. Endocrinol.,
June 1, 2003;
17(6):
1005 - 1018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. T. de Dios, D. Bruemmer, R. J. Dilley, M. E. Ivey, G. L.R. Jennings, R. E. Law, and P. J. Little
Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor-{gamma} Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell Proliferation
Circulation,
May 27, 2003;
107(20):
2548 - 2550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. T. Bloomgarden
Inflammation and Insulin Resistance
Diabetes Care,
May 1, 2003;
26(5):
1619 - 1623.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. R. Aroda and R. R. Henry
Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease
Diabetes Spectr,
April 1, 2003;
16(2):
120 - 125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Zangeneh, Y. C. Kudva, and A. Basu
Insulin Sensitizers
Mayo Clin. Proc.,
April 1, 2003;
78(4):
471 - 479.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A Defronzo
Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance?
The British Journal of Diabetes & Vascular Disease,
January 1, 2003;
3(1_suppl):
S24 - S40.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Carrillo-Jimenez, G. A. Lamas, and C. H. Hennekens
Thiazolidinediones Could Improve Endothelial Dysfunction and Risk of Premature Coronary Heart Disease in HIV-Infected Patients
Journal of Cardiovascular Pharmacology and Therapeutics,
December 1, 2002;
7(4):
207 - 210.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ishibashi, K. Egashira, K.-i. Hiasa, S. Inoue, W. Ni, Q. Zhao, M. Usui, S. Kitamoto, T. Ichiki, and A. Takeshita
Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone
Hypertension,
November 1, 2002;
40(5):
687 - 693.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Marso
Optimizing the diabetic formulary: beyond aspirin and insulin
J. Am. Coll. Cardiol.,
August 21, 2002;
40(4):
652 - 661.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Smith Jr, D. Faxon, W. Cascio, H. Schaff, T. Gardner, A. Jacobs, S. Nissen, and R. Stouffer
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: Revascularization in Diabetic Patients
Circulation,
May 7, 2002;
105
(18):
e165 - e169.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Molavi, N. Rasouli, and J. L. Mehta
Peroxisome Proliferator-Activated Receptor Ligands as Antiatherogenic Agents: Panacea or Another Pandora's Box?
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2002;
7(1):
1 - 8.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H. C. Lowe, S. N. Oesterle, and L. M. Khachigian
Coronary in-stent restenosis: Current status and future strategies
J. Am. Coll. Cardiol.,
January 16, 2002;
39(2):
183 - 193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Inzucchi
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
JAMA,
January 16, 2002;
287(3):
360 - 372.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Staels
The clinical significance of PPAR{alpha} and {gamma} agonism
The British Journal of Diabetes & Vascular Disease,
January 1, 2002;
2(1_suppl):
S28 - S31.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J S Sidhu and J C Kaski
Peroxisome proliferator activated receptor {gamma}: a potential therapeutic target in the management of ischaemic heart disease
Heart,
September 1, 2001;
86(3):
255 - 258.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Collins, W. P. Meehan, U. Kintscher, S. Jackson, S. Wakino, G. Noh, W. Palinski, W. A. Hsueh, and R. E. Law
Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor-Deficient Mice
Arterioscler Thromb Vasc Biol,
March 1, 2001;
21(3):
365 - 371.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|